Pharmaceutical firm Eli Lilly wins company of the year award
The US firm has been operating its biotechnology facility in Dunderrow, Kinsale, since 1981, providing what the judging panel described as “high-quality” development and manufacturing employment for more than 450 people in the area. More than €1 billion has been invested in the site over the past three decades, with current funding for expanding existing services reaching between €50-100 million per annum.
In 2007, the firm — which concentrates on Alzheimer’s, cancer and diabetes medications — began development on a new biotechnology facility at the site, investing almost €400m in the expansion, which is due to be opened by 2011, further increasing staff numbers in the region.
